Clinical trial · Interventional
Long-Term Follow-Up Study of Patients Receiving ATL001
An Open-Label, Multi-Centre Phase II Study Evaluating the Long-Term Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients Who Have Previously Received ATL001 in a Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The long-term follow-up of patients is being migrated to the original (parent) study protocols (Trial ID: ATX-NS-001 / NCT: NCT04032847;Trial ID: ATX-ME-001 / NCT: NCT03997474). Consequently, the ATX-LTFU-001 study is being terminated by the Sponsor.
Summary
Brief summary (as posted)
This is an Open-Label, Multi-Centre Phase II study to evaluate the long-term safety and clinical activity of ATL001, previously administered intravenously to patients in Study ATX-NS-001 (NCT04032847) or Study ATX-ME-001 (NCT03997474).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological: ATL001 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Experimental: ATL001
- description
- Patients who have previously received ATL001 in a clinical trial will be evaluated in this trial for long-term safety and clinical activity.
- interventionNames
- Other: Biological: ATL001
- type
- OTHER
- label
- Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001
- description
- Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001
- interventionNames
- Other: Biological: ATL001
Primary outcomes (4)
- measure
- Assessment of adverse events to evaluate long-term Safety and Tolerability of ATL001
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients must have given written informed consent to participate in the study. 2. Patients must have received ATL001 in a previous Clinical Trial. 3. Patients must be considered, in the opinion of the Investigator, capable of complying with the protocol requirements. Exclusion Criteria: There are no exclusion criteria.
References
Publications (0)
Data not yet available